Home β€Ί Stock analysis β€Ί BMGL

Basel Medical (BMGL) Stock: Why It Moved Today

Updated Oct 20, 2026, 1:16 PM ET Β· intraday price

What changed since yesterday
Compare with peers today

Hims & Hers Health (HIMS)Teladoc Health (TDOC)Starling Oncology (STLN)LifeMD (LFMD)Airsculpt Technologies (AIRS)SBC Medical (SBC)

BMGL is flat (+0.1%) to $4.05, 4 up days in a row. Trading at $4.05 (intraday, 1:16 PM ET), +0.12% vs the prior close of $4.05. Day range $4.05–$4.29, opened at $4.08.

Price (intraday)$4.05+0.12%
Day range4.05–4.29
Open4.08
Volume1.02M
52-week range2.56–21.72
Avg volume (20d)470.74K

BMGL daily analysis β€” what happened

A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.

Oct 20, 2026 β€” BMGL is flat (+0.1%) to $4.05, 4 up days in a row
Oct 19, 2026 β€” BMGL rises 2.5% to $4.05 on 2.2x normal volume
Oct 16, 2026 β€” BMGL rises 1.0% to $3.95 on 1.9x normal volume
Oct 15, 2026 β€” BMGL rises 1.6% to $3.91 on 2.0x normal volume
Oct 14, 2026 β€” BMGL ends flat (+0.0%) to $3.85 on 2.3x normal volume
Oct 13, 2026 β€” BMGL jumps 3.8% to $3.85
Oct 12, 2026 β€” BMGL dips 1.1% to $3.71
Oct 9, 2026 β€” BMGL jumps 4.2% to $3.75
Oct 8, 2026 β€” BMGL jumps 9.8% to $3.60
Oct 7, 2026 β€” BMGL dips 1.5% to $3.28
Oct 6, 2026 β€” BMGL jumps 5.0% to $3.33
Oct 5, 2026 β€” BMGL slides 3.4% to $3.17
Oct 2, 2026 β€” BMGL jumps 8.6% to $3.28

BMGL bull case vs bear case (from the data)

Bull case
  • No clear positive signal in the price trend, filings or insider data right now.
Bear case
  • Price is -8.4% vs its 50-day average β€” short-term trend is down.
  • Price is -38.8% vs its 200-day average β€” below the long-term trend line.
  • High volatility: average daily move of 3.8% over 20 sessions.
  • Thin trading (under $2M a day on average) can mean wide bid/ask spreads.

BMGL latest news & SEC filings

Every SEC filing by or about BMGL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.

Oct 13, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-046677

Oct 9, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-046409

Oct 8, 2026 Β· Form 424B4 β€” Final prospectus with offering price

Final prospectus with offering price

An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.

Source: SEC EDGAR filing 0001493152-26-046355

Oct 1, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001493152-26-045412

Sep 29, 2026 Β· Form EFFECT β€” EFFECT filing

EFFECT filing

Source: SEC EDGAR filing 9999999995-26-003102

Sep 23, 2026 Β· Form F-1/A β€” F-1/A filing

F-1/A filing

Source: SEC EDGAR filing 0001493152-26-043922

Sep 17, 2026 Β· Form F-1 β€” F-1 filing

F-1 filing

An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.

Source: SEC EDGAR filing 0001493152-26-043116

Sep 2, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-041151

Aug 10, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-036732

Jul 31, 2026 Β· Form DRS β€” DRS filing

DRS filing

Source: SEC EDGAR filing 0001493152-26-035580

Jul 22, 2026 Β· Form 3 β€” New insider holdings

Initial insider ownership statement (Form 3) β€” a new director, officer or 10% owner disclosed their holdings

Source: SEC EDGAR filing 0001493152-26-034159

Jul 10, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-032762

Jun 26, 2026 Β· Form 6-K β€” Report from a foreign company (6-K)

Report from a foreign company (6-K) β€” news it published at home

Source: SEC EDGAR filing 0001493152-26-030234

Things to know before you trade BMGL

BMGL market data (last 20 sessions)

DateOpenHighLowCloseVolume
Oct 20, 20264.084.294.054.051.02M
Oct 19, 20263.934.113.774.051.74M
Oct 16, 20263.973.973.803.951.45M
Oct 15, 20263.943.943.783.911.44M
Oct 14, 20263.884.143.753.851.60M
Oct 13, 20263.874.173.713.851.14M
Oct 12, 20263.574.303.573.71471.50K
Oct 9, 20263.503.883.433.75104.00K
Oct 8, 20263.203.742.563.60126.90K
Oct 7, 20263.203.303.183.2812.60K
Oct 6, 20263.253.333.203.339.60K
Oct 5, 20263.223.553.173.1713.40K
Oct 2, 20263.053.352.953.2825.20K
Oct 1, 20263.123.253.023.0210.40K
Sep 30, 20263.313.313.033.127.00K
Sep 29, 20263.433.443.043.10130.50K
Sep 28, 20263.703.703.453.4712.70K
Sep 25, 20263.803.843.683.704.70K
Sep 24, 20264.094.093.703.8061.50K
Sep 23, 20264.084.243.884.0940.90K

About Basel Medical

Basel Medical (BMGL) is listed on the Nasdaq and classified by the SEC under β€œServices-Offices & Clinics of Doctors of Medicine”. Its business address is in SINGAPORE, Singapore. State of incorporation: Virgin Islands, British. Fiscal year ends June 30. SEC CIK 2004489.

BMGL board of directors & executives

From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).

Directors

NameRoleLatest filing
Tony ChenDirectorApr 14, 2026
Paul D FreudenthalerDirectorMar 4, 2026
Keng Leong FungDirectorApr 14, 2026
Kwek Yoon SoongDirectorApr 21, 2026
Boon Chye TanChief Commercial OfficerApr 14, 2026

Executive officers

NameTitleLatest filing
Darren Yen Feng ChhoaChief Executive OfficerApr 14, 2026
Jianing Jn LuChief Financial OfficerApr 15, 2026
Alton Chun How NeoInterim CFOJul 22, 2026
Boon Chye TanChief Commercial OfficerApr 14, 2026

Recent insider buys & sales

DateInsiderTypeSharesPrice
No open-market insider buys or sales reported in the last 12 months.

BMGL financials (annual, from XBRL filings)

Fiscal year endRevenueNet incomeDiluted EPSOperating cash flow
No annual XBRL figures available (foreign filers often report on Form 20-F).

Latest balance sheet: total assets $β€”, total liabilities $β€”, cash $β€”.

BMGL earnings / results-day log

DateFilingClose that day
No 8-K earnings releases in recent filings.

Related stocks Β· Services-Offices & Clinics of Doctors of Medicine

Hims & Hers Health (HIMS)Teladoc Health (TDOC)Starling Oncology (STLN)LifeMD (LFMD)Airsculpt Technologies (AIRS)SBC Medical (SBC)Auna (AUNA)Westin Acquisition (WSTN)Concord Medical Services (CCM)

Popular today

Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)

More on BMGL

Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: intraday data as of Oct 20, 2026, 1:16 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.